Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Anna Blom receives the 2021 Berzelius Medal for advances in medical chemistry

Potrait of Professor Anna Blom , Lund University
Photo: Tove Smeds

Congratulations Anna Blom, Professor of Medical Protein Chemistry at Lund University and the recipient of the Swedish Society of Medicine’s Berzelius Medal in Gold 2021 for innovative research in the field of medical chemistry.

How does it feel to receive this prestigious award?

– It’s a great honour for me to be awarded the Berzelius Medal and for our research to receive such notice. I began my postdoc training in clinical chemistry in Malmö in 1998, under the supervision of Professor Björn Dahlbäck, a distinguished coagulation researcher and clinical chemist. At the same time, I had the pleasure of following the research conducted by Professor Johan Stenflo’s research team. I was also well-acquainted with Professor Inga-Maria Nilsson and Professor Carl Laurell, former prominent clinical chemists from Malmö. It’s truly an honour to be able to continue conducting medical chemical research in their footsteps.

What significance does your research have for human health?

– Our research is focused on the complement system, which is part of the innate immune system. The complement system plays a significant role in many basic biological processes, such as defence against infections. But when the system is incorrectly activated, it can contribute to a variety of diseases, including rheumatic diseases and kidney and eye diseases.

– Our ambition is to conduct basic, high-quality research based on clinically relevant issues, thus laying the groundwork for new diagnostic methods. For example, in collaboration with Answer Life Science (ANSWER), our research team has produced a blood test for patients with severe rheumatic disease that enables better diagnostics and treatment. This so-called “C4d test” is a blood test that measures the biomarker C4d in the blood, and it’s already available internationally. Moving forward, we also want to develop new therapies and improve the selection of patients who can be treated with complement inhibitors, which are currently being developed by several different pharmaceutical companies.

What exciting research projects are you working on?

– Since the complement system is involved in many different conditions, we’re studying its role in cancer development, in infection, in rheumatic diseases, and now even in diabetes. The most scientifically exciting project right now focuses on new roles that complement proteins play inside cells, such as in pancreatic beta cells. Here we study how C3 protects cells by regulating autophagy and how CD59 contributes to the secretion of insulin, both of which are relevant in terms of diabetes.

– The most clinically exciting projects focus on the development and evaluation of diagnostic tests with complement biomarkers and studies of how COMP, a protein found in connective tissue, contributes to the development of different types of cancer, and whether it can be used as the basis for new treatment.

Link to original arcticle published by Tove Gilad 22 September 2021

About the Berzelius Medal

The Berzelius Medal in Gold is awarded every ten years and was established in 1898 in honour of the memory of Jacob Berzelius, one of the founders of the Swedish Society of Medicine. The prize awards scientists whose work has made the greatest contributions to advances in medical chemistry.

The award ceremony will be held on 9 November 2021 at the headquarters of the Swedish Society of Medicine.